ABSI
Absci Corporation
Biotechnology · Healthcare · United States
11.13
close · 2026-10-30
value
57
cheaper than peers57
quality
34
stronger fundamentals34
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -3.4% | 71 |
| cash flow yield, 1 year ago | -3.8% | 71 |
| cash flow yield, latest year | -4.9% | 64 |
| earnings yield, 1 year ago | -8.4% | 62 |
| earnings yield, 2 years ago | -10.8% | 60 |
| earnings yield, 3 years ago | -10.3% | 60 |
| earnings yield, latest year | -7.5% | 59 |
| cash flow yield, 3 years ago | -5.1% | 58 |
| price to book | 7.76× | 23 |
| price to sales | 1040.34× | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.6% | 83 |
| return on equity | -63.9% | 38 |
| revenue growth | -81.8% | 8 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$41.5M |
| employees | 140 |
| first trade | 2021-07-22 |
| next earnings | 2026-11-12 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.84 | -0.94 | -1.20 | -1.15 |
| free cash flow | -$94.0M | -$72.8M | -$65.5M | -$97.5M |
| net income | -$115.2M | -$103.1M | -$110.6M | -$104.9M |
| revenue | $2.8M | $4.5M | $5.7M | $5.7M |
| unusual items | $5.1M | $0 | -$21.3M | $0 |